Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Orally Disintegrating Tablet Market Size And Revenue Outlook Through 2030
The orally disintegrating tablet market has demonstrated robust growth in recent years. It is forecast to rise from $16.2 billion in 2025 to $17.62 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The historical period’s expansion was influenced by limited familiarity with orally disintegrating tablets, the dominance of traditional tablets, inadequate targeting for pediatric and geriatric populations, reliance on hospital pharmacy avenues, and a slow pace in adopting specialty drug formulations.
The orally disintegrating tablet market is projected to witness significant expansion in the coming years. Its valuation is expected to reach $24.43 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The expansion during this forecast period can be attributed to technological breakthroughs in ODT formulation, an increasing patient preference for convenience and adherence, the development of online and retail pharmacy networks, a rising incidence of central nervous system and gastrointestinal disorders, and augmented research and development in antipsychotics and antiepileptics. Key trends anticipated in the forecast period include a growing demand for easy-to-swallow and patient-friendly dosage forms, an expansion in targeting pediatric and geriatric patient populations, growth in hospital and retail pharmacy distribution channels, an increased focus on rapid-onset therapeutics, and the rising adoption of specialty drug classes in ODT formulations.
Get A Free Sample Report With In-Depth Market Insights:
Orally Disintegrating Tablet Market Demand Drivers: What’s Powering Industry Growth?
The escalating occurrence of neurological disorders is set to fuel the growth of the orally disintegrating tablet market in the future. Neurological disorders are health conditions impacting the nervous system, encompassing the brain and peripheral nerves, which disrupt its normal functioning. The rise in these conditions is largely due to longer lifespans, as ailments like Alzheimer’s and Parkinson’s become more common with advancing age, leading to an overall increase in cases. Orally disintegrating tablets assist in managing neurological disorders by enabling simpler and quicker medication administration, especially for patients facing swallowing difficulties (dysphagia) or cognitive impairments, thereby improving treatment adherence, ensuring timely dosing, and enhancing the overall efficacy of therapy. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, stated that in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating a surge to 13.8 million by 2060. Consequently, the increasing incidence of neurological disorders is propelling the expansion of the orally disintegrating tablet market.
Orally Disintegrating Tablet Market Segmentation: How Does The Market Break Down By Category?
The orally disintegrating tablet market covered in this report is segmented –
1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
4) By Consumer Type: Pediatric, Adult, Geriatric
Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole
10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes
Orally Disintegrating Tablet Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the orally disintegrating tablet market are concentrating on innovating drug formulations, particularly patient-centric drug delivery systems, to bolster treatment adherence and improve patient outcomes. A patient-centric drug delivery system involves creating and administering medicines in a way that is easier and more comfortable for patients, consequently enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, introducing a novel treatment choice for treatment-resistant schizophrenia. It provides several distinctive attributes, positioning it as a significant contribution to the management of treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) accessible in the country, it presents a patient-friendly alternative that quickly dissolves in the mouth without water, assisting individuals with swallowing difficulties or adherence issues. The product is offered in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for flexible and precise dose titration based on a patient’s specific requirements. By incorporating clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation supports alignment with established treatment protocols.
Orally Disintegrating Tablet Market Competitive Overview And Top Companies
Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.
View The Full Orally Disintegrating Tablet Market Report:
Orally Disintegrating Tablet Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model